Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM3TO27)

Drug Name
saclofen Drug Info
Synonyms
saclofen; 125464-42-8; 3-amino-2-(4-chlorophenyl)propane-1-sulfonic acid; beta-(Aminomethyl)-4-chlorobenzeneethanesulfonic acid; CHEMBL312403; (RS)-3-amino-2-(4-chlorophenyl)propylsulfonic acid; AK-86940; Benzeneethanesulfonic acid, beta-(aminomethyl)-4-chloro-; 3-AMINO-2-(4-CHLOROPHENYL)-PROPANE SULFONIC ACID; Saclofen, solid; Saclofen HCl; Biomol-NT_000242; SCHEMBL339757; BPBio1_000705; GTPL1078; AC1L3U31; CHEBI:91596; CTK8B4660; MolPort-003-824-767; HMS3266E05; BCP16740; BN0452; ANW-45829; MFCD00216817; BDBM50286225
Cross-matching ID
PubChem CID
122150
ChEBI ID
CHEMBL312403
CAS Number
CAS 125464-42-8
TTD Drug ID
D0S5YH

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Hematopoietic cell lineage 1.91 4.24e-2 90/99 (90.91%) CD9;CD59;CD2;...
DNA replication 1.86 3.77e-2 34/36 (94.44%) MCM6;POLE2;FEN1;...
Retinol metabolism 1.84 3.06e-2 41/68 (60.29%) CYP3A5;UGT2B4;CYP3A4;...
Allograft rejection 1.84 2.45e-2 32/38 (84.21%) GZMB;PRF1;HLA-DRA;...
T cell receptor signaling pathway 1.84 2.04e-2 93/104 (89.42%) NFATC3;LCK;CD247;...
Natural killer cell mediated cytotoxicity 1.82 1.88e-2 99/131 (75.57%) GZMB;LCK;KLRK1;...
Systemic lupus erythematosus 1.80 2.24e-2 45/135 (33.33%) C1S;C1R;C1QA;...
Graft-versus-host disease 1.80 1.99e-2 32/42 (76.19%) GZMB;PRF1;HLA-DRA;...
Basal transcription factors 1.74 3.01e-2 37/45 (82.22%) GTF2I;GTF2IRD1;GTF2H4;...
Asthma 1.72 3.34e-2 25/31 (80.65%) FCER1A;HLA-DRA;HLA-DQA1;...
Fc epsilon RI signaling pathway 1.70 3.92e-2 57/68 (83.82%) FCER1A;RAC2;ALOX5AP;...
Cell cycle 1.70 3.69e-2 110/124 (88.71%) CDC20;CCNA2;MCM6;...
Antigen processing and presentation 1.69 3.63e-2 60/78 (76.92%) CD8A;CD74;HSPA8;...
Fanconi anemia pathway 1.67 3.89e-2 36/54 (66.67%) BLM;REV3L;RAD51C;...
Human T-cell leukemia virus 1 infection 1.64 4.65e-2 197/219 (89.95%) CDC20;MMP7;NFATC3;...
Th1 and Th2 cell differentiation 1.62 4.82e-2 80/92 (86.96%) NFATC3;LCK;CD247;...
ECM-receptor interaction -2.06 0.00e+0 80/88 (90.91%) COL1A1;ITGA2;THBS4;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 10uM 6H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 10uM 6H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 10uM 6H, 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 1.11uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 1.11uM - 10uM 6H, 24H